SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): December 1995
BIOPHARMACEUTICS, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 1-9370 13-3186327
(State or other (Commission File Number) (I.R.S Employer
jurisdiction of I.D. Number)
incorporation)
990 Station Road
Bellport, New York 11713
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (516)286-5800
N/A
(Former name or former address, if changed since last report.)
1
<PAGE>
Item 5. Other Events
By court order dated December 20, 1995, the United States District
Court for the Eastern District of New York dismissed all claims by
Biopharmaceutics, Inc. and Biopharm Lab, Inc. against Primavera
Laboratories, Inc. and Avon Products, Inc. and granted the counterclaim by
Primavera Laboratories, Inc. effectively terminating the license the Company
held to sell its personal care product "Treo". The Company intends to appeal the
decision.
EXHIBIT INDEX
Current Report on Form 8-K
of
Biopharmaceutics, Inc.
Date of Report: December 28, 1995
Exhibits:
28.9 Court order dated December 20, 1995 (Order received December 21, 1995)
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHARMACEUTICS, INC.
(Registrant)
By: /s/ Edward Fine
--------------------
Edward Fine
President, Chief Executive Officer
(Signature)
Dated: December 28, 1995
3
<PAGE>
